Enriching the Power of Sequencing
Roche Pioneers NGS Target Enrichment
Target enrichment allows scientists to focus sequencing resources by selectively working from only the DNA of interest from a sample. This leads to reduced costs and simplified analysis, but it also can enable scientists to address more challenging genetic questions through increased sequencing depth.
As the pioneer in hybridization-based target enrichment, Roche Sequencing continues to expand its best-in-class offerings to address new technologies, new applications and the changing needs of scientists.
HEAT-Seq Enrichment Systems provide an amplification-based enrichment method that combines a fast and easy workflow with powerful SNV detection for targeted resequencing applications in human genetic disease and cancer research.
The SeqCap EZ MedExome Target Enrichment Kit incorporates innovative probe design approaches and improved molecular methodologies to deliver a comprehensive whole exome sequencing solution for human genome analysis with enhanced coverage of disease-associated regions.
NEW SeqCap EZ HyperCap Workflow User's Guide for use with the SeqCap EZ target enrichement products. The SeqCap EZ HyperCap Workflow provides an integrated workflow solution that combines high-efficiency library preparation kits from KAPA with performance-optimized SeqCap capture protocol. It is an application-specific approach for efficient, streamlined and automatable targeted sequencing.
Roche has partnered with the Garvan Institute of Medical Research to develop new targeted epigenetic analysis technologies. The collaboration brings together the world-leading genomics expertise and infrastructure at the Garvan Institute and the best-in-class products for target enrichment from Roche NimbleGen. Scientists at the Garvan Institute will use SeqCap Target Enrichment products to further their research in epigenetic influences on human diseases.
Roche has obtained exclusive rights to AbVitro primer extension based target enrichment technology. Under the terms of the agreement, AbVitro and Roche scientists will collaborate on the development and application of the technology. The primer extension based target enrichment (PETE) technology will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications.